What is Monobind?
Founded in 1978 and headquartered in Costa Mesa, California, Monobind has established itself as a leader in diagnostic development and innovation. The company boasts a substantial manufacturing history, having produced over 200 million immunoassays, positioning it among the largest in-vitro diagnostic producers globally. Monobind's reach extends to more than 30 countries, supplying assays, diagnostic tools, and biological raw materials to a diverse clientele including biomedical researchers, laboratories, manufacturers, and distributors. Renowned for quality, reliability, and cost-effectiveness, Monobind leverages its pioneering experience and recognized R&D authority to deliver products that set industry standards in diagnostic healthcare.
How much funding has Monobind raised?
Monobind has raised a total of $898K across 2 funding rounds:
Debt
$350K
Debt
$548K
Debt (2020): $350K with participation from PPP
Debt (2021): $548K led by PPP
Key Investors in Monobind
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Monobind?
The recent major strategic investment signals a pivotal phase for Monobind, likely aimed at accelerating its expansion in global markets and further solidifying its R&D capabilities. This capital infusion is expected to fuel innovation in diagnostic development, potentially leading to the introduction of new assays and diagnostic tools. Monobind's established reputation and extensive product portfolio suggest a strategic focus on enhancing its market share and deepening its relationships with existing partners while exploring new avenues for growth in the dynamic healthcare sector.
See full Monobind company page
